Advancing Long-Acting Treatments for HIV, Tuberculosis, and Viral Hepatitis
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
This program helps speed up the creation of new, longer-lasting medications and technologies for people living with HIV, tuberculosis, and viral hepatitis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11084860 on NIH RePORTER |
What this research studies
Our program works with researchers, drug companies, and community groups to overcome challenges in developing new long-acting treatments. We provide a website to track the latest scientific progress and regulatory approvals for these new products, and we use advanced computer modeling to predict which drug candidates and dosing schedules are most promising. Our goal is to make it easier to develop innovative treatments like anti-HIV implants and microneedles, especially for specific groups like infants, children, adolescents, and pregnant women.
Who could benefit from this research
Good fit: This program aims to benefit patients with HIV, tuberculosis, or viral hepatitis, including infants, children, adolescents, and pregnant women, by accelerating the development of new treatment options.
Not a fit: Patients not affected by HIV, tuberculosis, or viral hepatitis would not directly benefit from the specific drug development efforts supported by this program.
Why it matters
Potential benefit: If successful, this work could lead to more convenient and effective long-acting treatments for HIV, tuberculosis, and viral hepatitis, improving patient adherence and quality of life.
How similar studies have performed: This program has already made significant contributions, including providing foundational input for regulatory guidance and promoting the development of the first long-acting candidates for tuberculosis and viral hepatitis.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Flexner, Charles W. — Johns Hopkins University
- Study coordinator: Flexner, Charles W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.